NerveX Neurotechnologies
Dr. Mark de Wolde DVM MRCVS is a distinguished veterinary professional with extensive experience in leadership and consultancy roles. As Co-Founder and Chief Veterinary Officer of NerveX and Co-Founder and Medical Director of myVETgroup, Dr. de Wolde has significantly contributed to veterinary practice innovation. Dr. de Wolde also serves as President of Lenio Pharmaceuticals Inc. and as a Veterinary Consultant for DrugSmart Pharmacy Group. Additionally, involvement as a mentor for the Scotiabank Women's Initiative through The Forum highlights a commitment to supporting emerging leaders in the field. Dr. de Wolde holds a Doctor of Veterinary Medicine degree from Ontario Veterinary College, University of Guelph, and has furthered education at Utrecht University.
This person is not in the org chart
This person is not in any teams
NerveX Neurotechnologies
NerveX has developed ANIMO, the adaptive neural implant for modulation and observation. ANIMO is a vessel to implant our proprietary machine learning and responsive electrical neuromodulation technology to repair and augment the nervous system.